tert-butyl 4-cyano-4-(dimethylamino)piperidine-1-carboxylate | 849928-27-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-cyano-4-(dimethylamino)piperidine-1-carboxylate
• 英文别名: tert-butyloxycarbonyl-4-cyano-4-(dimethylamino)piperidine
• CAS: 849928-27-4
• 化学式: C₁₃H₂₃N₃O₂
• 分子量: 253.345
• InChiKey: COVRYKGBHLVHIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  56.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-cyano-4-(dimethylamino)piperidine-1-carboxylate 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 16.25h， 生成 tert-butyl (3-(4-(dimethylamino)-4-phenylpiperidin-1-yl)-3-oxopropyl)carbamate
  参考文献：
  名称：

  [EN] SUBSTITUTED INDOLE DERIVATIVES
  [FR] DÉRIVÉS D'INDOLE SUBSTITUÉS

  摘要：

  本发明涉及具有一般式（I）的取代吲哚衍生物，其作用于ORL 1受体，其中A和B相互独立地表示CH2、C=O或SO2，X代表吲哚基，未取代或单取代或多取代；T代表（CR5a-cR6a-c）n，n = 1、2或3，Q代表（CR7a-cR8a-c）m，m = 0、1、2或3，以及其制备方法、含有这些化合物的药物和用于制备药物的取代吲哚衍生物的用途。

  公开号：

  WO2009103552A1
• 作为产物：
  描述：

  potassium cyanide 、 N-叔丁氧羰基-4-哌啶酮 、 二甲胺 在 溶剂黄146 作用下， 以 甲醇 为溶剂， 生成 tert-butyl 4-cyano-4-(dimethylamino)piperidine-1-carboxylate
  参考文献：
  名称：

  Substituted indole derivatives

  摘要：

  取代吲哚衍生物，其制备方法，含有这些化合物的药品和药物组合物，以及利用取代吲哚衍生物治疗疼痛和其他症状以及其他医学用途。

  公开号：

  US20090215828A1

文献信息

• Substituted Indole Compounds
  申请人：Schunk Stefan

  公开号：US20100222324A1

  公开（公告）日：2010-09-02

  Substituted indole compounds corresponding to the formula I: In which R 8 , R 9a , R 9b , R 10 , R 11 , R 200 , R 210 , A, D, T, q, s and t have defined meanings, processes for the preparation thereof, pharmaceutical compositions containing such compounds and the use of substituted indole compounds for the treatment or inhibition of pain and other conditions which are at least partly mediated by Bradykinin 1 receptors (B1R).

  将与下式I对应的吲哚化合物替代： 其中R8、R9a、R9b、R10、R11、R200、R210、A、D、T、q、s和t具有定义的含义，其制备方法，含有这种化合物的药物组合物以及用于治疗或抑制至少部分由Bradykinin 1受体（B1R）介导的疼痛和其他病症的替代吲哚化合物的用途。
• Substituted Pyrimidine and Triazine Compounds
  申请人：Schunk Stefan

  公开号：US20100173889A1

  公开（公告）日：2010-07-08

  Substituted pyrimidine and triazine compounds corresponding to formula I wherein R 1 , R 2 , R 3 , R 4a , R 4b , R 5a , R 5b , R 7 , R 8 , R 9a , R 9b , R 10 , R 11 , A, a, b, s, t, V, W 1 , W 2 and W 3 have defined meanings, pharmaceutical compositions comprising such compounds, a process for preparing such compounds, and the use of such compounds and compositions to treat or inhibit pain and/or other disorders or disease states.

  将对应于公式I的嘧啶和三嗪化合物替代为R1、R2、R3、R4a、R4b、R5a、R5b、R7、R8、R9a、R9b、R10、R11、A、a、b、s、t、V、W1、W2和W3具有定义意义，包括这种化合物的药物组合物、制备这种化合物的过程，以及使用这种化合物和组合物来治疗或抑制疼痛和/或其他疾病状态的专利。
• Substituted pyrimidine and triazine compounds
  申请人：Gruenenthal GmbH

  公开号：US08269000B2

  公开（公告）日：2012-09-18

  Substituted pyrimidine and triazine compounds corresponding to formula I wherein R1, R2, R3, R4a, R4b, R5a, R5b, R7, R8, R9a, R9b, R10, R11, A, a, b, s, t, V, W1, W2 and W3 have defined meanings, pharmaceutical compositions comprising such compounds, a process for preparing such compounds, and the use of such compounds and compositions to treat or inhibit pain and/or other disorders or disease states.

  替代嘧啶和三嗪化合物，对应于式I，其中R1、R2、R3、R4a、R4b、R5a、R5b、R7、R8、R9a、R9b、R10、R11、A、a、b、s、t、V、W1、W2和W3具有定义的含义，包括此类化合物的制药组合物、制备此类化合物的方法，以及使用此类化合物和组合物治疗或抑制疼痛和/或其他疾病状态或疾病的用途。
• Substituted indole compounds
  申请人：Schunk Stefan

  公开号：US08492559B2

  公开（公告）日：2013-07-23

  Substituted indole compounds corresponding to the formula I: In which R8, R9a, R9b, R10, R11, R200, R210, A, D, T, q, s and t have defined meanings, processes for the preparation thereof, pharmaceutical compositions containing such compounds and the use of substituted indole compounds for the treatment or inhibition of pain and other conditions which are at least partly mediated by Bradykinin 1 receptors (B1R).

  本发明涉及一种对应于式I的取代吲哚化合物：其中R8、R9a、R9b、R10、R11、R200、R210、A、D、T、q、s和t具有定义的含义，其制备过程，含有这种化合物的制药组合物以及使用取代吲哚化合物治疗或抑制至少部分通过Bradykinin 1受体（B1R）介导的疼痛和其他病症。
• Discovery of dual-acting opioid ligand and TRPV1 antagonists as novel therapeutic agents for pain
  作者：Hobin Lee、Songyeon Ahn、Jihyae Ann、Heejin Ha、Young Dong Yoo、Young Ho Kim、Ji-Young Hwang、Kwang-Hyun Hur、Choon-Gon Jang、Larry V. Pearce、Timothy E. Esch、Nancy E. Lewin、Peter M. Blumberg、Jeewoo Lee

  DOI：10.1016/j.ejmech.2019.111634

  日期：2019.11

  In order to discover a novel type of analgesic, we investigated dual activity ligands with TRPV1 antagonism and mu-opioid receptor affinity with the goal of eliciting synergistic analgesia while avoiding the side effects associated with single targeting. Based on a combination approach, a series of 4-benzyl-4-(dimethylamino)piperidinyl analogues were designed, synthesized and evaluated for their receptor activities. Among them, compound 49 exhibited the most promising dual-acting activity toward TRPV1 and the mu-opioid receptor in vitro. In vivo, 49 displayed potent, dose-dependent antinociceptive activity in both the 1st and 2nd phases in the formalin assay. Consistent with its postulated mechanism, we confirmed that in vivo, as in vitro, compound 49 both antagonized TRPV1 and functioned as a mu-opioid agonist. This result indicates that dual-acting TRPV1 antagonist/mu-opioid ligands can be made and represent a new and promising class of analgesic. (C) 2019 Elsevier Masson SAS. All rights reserved.